GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024 Galmed Pharmaceuticals (NASDAQ: GLMD ) just reported results for the first quarter of 2024. Galmed Pharmaceuticals reported earnings per share of -23 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024 appeared first on InvestorPlace .
Galmed Pharmaceuticals Calls for Shareholder Votes Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has announced its Annual General Meeting of Shareholders to be he…
Galmed Pharma Reports Q1 2024 Financials Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. reported a condensed consolidated financial overview for the firs…
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 Now could be a great time for investors to consider stacking up on penny stocks . These companies often have significant growth potential. But they trade at low prices, typically under $5 per share. Penny stocks tend to be highly volatile, with the potential for rapid gains or losses. This requires careful research and risk management. Fortunately, some of the better-known penny stocks are covered by Wall Street analysts who give strong buy ratings. This is a positive indicator, as analysts closely follow the fundamentals, growth prospects and catalysts for these companies. Many penny stocks are speculative investments since the underlying companies may be new, unprofitable or in uncertain industries. Ratings given by these analysts could then mitigate some risk. But some great bargains are in the market right now. So, let’s examine three penny stocks to buy with strong buy ratings in April. Galmed Pharmaceuticals (GLMD) Source: Billion Photos / Shutterstock Galmed Pharmaceuticals (NASDAQ: GLMD ) focuses on the development of therapies for liver diseases, including non-alcoholic steatohepatitis ( NASH ).
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023 Galmed Pharmaceuticals (NASDAQ: GLMD ) just reported results for the fourth quarter of 2023. Galmed Pharmaceuticals reported earnings per share of -98 cents. This was below the analyst estimate for EPS of -32 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023 appeared first on InvestorPlace .
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 TEL AVIV, Israel , April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC").
Galmed Pharmaceuticals Granted Nasdaq Extension Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has been granted an additional 180-day period by Nasdaq to meet t…
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis TEL AVIV, Israel , March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday Pre-market stock movers are a hot topic on Tuesday morning and we’ve got all of the coverage traders need to know about them today! There’s plenty of earnings reports and other news moving stocks this morning. Let’s get into that news down below! Biggest Pre-Market Stock Movers: 10 Top Gainers MariaDB (NYSE: MRDB ) stock is rocketing more than 137% with heavy trading despite failing to repay a senior secured promissory note . MicroCloud Hologram (NASDAQ: HOLO ) shares are soaring over 39% on plans to join the Communications Industry Association . Psyence Biomedical (NASDAQ: PBM ) stock is surging more than 23% with strong pre-market trading. GRIID Infrastructure (NASDAQ: GRDI ) shares are gaining over 19% on plans for a new crypto mining facility . Zapp Electric Vehicles (NASDAQ: ZAPP ) stock is increasing more than 17% without any clear news this morning. Solidion Technology (NASDAQ: STI ) shares are rising over 15% on Wednesday. Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is heading more than 15% higher today.